China Institute of Veterinary Drug Control

H6 subtype avian influenza viruses (AIVs) have a broader host range and circulate globally in wild birds, domestic ducks, geese, and terrestrial poultry all over the world. Their demonstrated capacity to adapt receptor-binding affinity for mammalian species constitutes a persistent concern for zoonotic transmission and public health. In this study, a novel triple-reassortant H6N8 AIV strain was isolated from a chicken farm in southern China and designated as A/chicken/Guangdong/JM642/2023 (H6N8). The complete genome of the virus was sequenced using Next-Generation Sequencing. Phylogenetic analysis indicated that the HA gene of the isolate clustered into the Group III/HN573-like, which encompasses H6 subtype viruses bearing various NA genes and belonging to the Eurasian gene pool. The NA gene showed the closest genetic relationship with viruses originating from North America. All six internal genes were derived from H9N2 AIVs. The virus possesses several key molecular determinants known to contribute to an expanded host range and increased virulence. Animal infection studies demonstrated that the virus was capable of infecting mice without prior adaptation. It replicated efficiently in the lungs and nasal turbinates, followed by systemic dissemination resulting in lethal outcomes. Inoculated chickens remained asymptomatic; however, the virus replicated efficiently in multiple organs, with high viral loads detected particularly in the lungs and kidneys. Viral shedding occurred via both the respiratory and digestive tracts, and horizontal transmission was observed among chickens. Notably, infected and contacted chickens developed high levels of antibodies from 8 days post-inoculation (DPI) to the end of observation period. This study enhances our understanding of the genetic and biological characteristics of the novel reassortant H6N8 AIVs and underscores their potential risk to public health.

Host-pathogen interactions are shaped by cellular restriction factors that direct antiviral defenses. We built the first ovine genome-wide CRISPR knockout library in sheep testis (OA3.Ts) cells, targeting all protein-coding genes. Using this platform, we identified PEX11B, a peroxisomal membrane regulatory protein, as a strong restriction factor against orf virus (ORFV) infection. Removing PEX11B increased viral susceptibility and triggered severe cytopathic effects with membrane fusion and syncytia formation. Mechanistic studies showed that PEX11B knockout harmed peroxisomal integrity and disrupted lipid metabolism. This led to greater plasma membrane fluidity, creating a proviral environment that allowed more viral entry and replication. These results reveal a new antiviral function for PEX11B in blocking viral infection and underscore the importance of peroxisomal regulation in host-virus interactions.

African swine fever (ASF) is a highly pathogenic and hemorrhagic swine infectious disease caused by the African swine fever virus (ASFV). It encodes over 150 proteins, among which the CD2v protein plays multiple roles throughout the infection process. Single B-cell antibody technology is a cutting-edge method for preparing monoclonal antibodies (mAbs), which has the advantages of rapid, efficient, and high yield in antibody production, while possessing natural conformations. In this study, by cloning and expressing antibody genes in vitro, 14 murine-derived mAbs were prepared using recombinant CD2v proteins as immunogenic sources, which brings sufficient enrichment and selectivity for the development of antibodies based on the single B-cell antibody technique. All 14 mAbs demonstrated reactivity with CD2v protein by indirect ELISA, whereas 8 mAbs successfully detected CD2v in ASFV-infected PAM cells by IFA, indicating the tested mAbs can effectively recognize and bind to ASFV CD2v. Finally, a blocking ELISA method for detecting CD2v antibodies using CD2v mAb C89 was established, which holds significant potential for broad application in the serological diagnosis of ASFV with determination of the CD2v-blocking ELISA specificity, sensitivity, reproducibility, and compliance rate. It could be used for the rapid clinical detection of ASFV CD2v protein to provide a powerful tool for the monitoring of epidemics.

Abstract A FeCl3‐assisted electrophilic fluorine‐catalyzed 1,3‐rearrangement was developed, characterized by its mild catalytic system and broad substrate scope. The functional group tolerance of this approach was evaluated through a series of allylic alcohols readily prepared in situ from commercially available enones. Various nucleophiles, including water, amides, and Hantzsch esters, were utilized in the reaction. A plausible mechanism was proposed to elucidate the observed transformations, and the versatility of this methodology was demonstrated through the syntheses of asparenyn, gonicusin B, and the PPAR‐agonist NNC 61‐4655.

African swine fever virus (ASFV), a highly contagious pathogen characterized by a complex structure and a variety of immunosuppression proteins, causes hemorrhagic, acute, and aggressive infectious disease that severely injures the pork products and industry. However, there is no effective vaccine or treatment. The main reasons are not only the complex mechanisms that lead to immunosuppression but also the unknown functions of various proteins. This review summarizes the interaction between ASFV and the host immune system, along with the involvement of virulence-related genes and proteins, as well as the corresponding molecular mechanism of immunosuppression of ASFV, encompassing pathways such as cGAS-STING, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), Janus Kinase (JAK) and JAK Signal Transducers and Activators of Transcription (STAT), apoptosis, and other modulation. The aim is to summarize the dynamic process during ASFV infection and entry into the host cell, provide a rational insight into development of a vaccine, and provide a better clear knowledge of how ASFV impacts the host.

The rapid spread of bacteria with plasmid-mediated resistance to antibiotics poses a serious threat to public health. The search for potential compounds that can increase the antibacterial activity of existing antibiotics is a promising strategy for addressing this issue. Synergistic activity of the FDA-approved agent oxethazine combined with colistin was investigated in vitro using checkerboard assays and time-kill curves. The synergistic mechanisms of their combination of oxethazine and colistin was explored by fluorescent dye, scanning electron microscopy (SEM) and LC-MS/MS. The synergistic efficacy was evaluated in vivo by the Galleria mellonella and mouse sepsis models. In this study, we found that oxethazine could effectively enhance the antibacterial activity of colistin against both mcr-positive and -negative pathogens, and mechanistic assays revealed that oxethazine could improve the ability of colistin to destruct bacterial outer membrane and cytoplasmic membrane permeability. In addition, their combination triggered the accumulation of reactive oxygen species causing additional damage to the membrane structure resulting in cell death. Furthermore, oxethazine significantly enhanced the therapeutic efficacy of colistin in two animal models. These results suggested that oxethazine, as a promising antibiotic adjuvant, can effectively enhance colistin activity, providing a potential strategy for treating multidrug-resistant bacteria.